Trastuzumab deruxtecan demonstrates advance in treatment for HER2-positive gastric cancer

IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma

Zanzalintinib plus atezolizumab improves survival in refractory mCRC

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC

Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC

Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource-constrained settings

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer

Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer

Bladder cancer updates from the first half of 2025

Improving efficacy and toxicity reporting - and treatment insights from an oncologist patient

WCLC 2025: Latest in EGFR positive NSCLC